Liposome imaging agents in personalized medicine

Area of Science:

• Nanomedicine
• Molecular Imaging
• Theranostics

Background:

• The significance of molecular and diagnostic imaging in disease treatment planning, especially in oncology, has grown substantially.
• Nanomedicine offers promising avenues for integrating imaging and therapeutic functionalities.
• Engineered liposomes can target tumor tissues, delivering both drugs and imaging agents for a theranostic approach.

Purpose of the Study:

• To review recent advancements in radiolabeled liposomes for molecular imaging.
• To highlight the role of these agents in personalized medicine, including patient selection and treatment monitoring.
• To explore the potential of nanocarrier imaging agents in disease diagnostics and staging.

Main Methods:

• Review of literature on radiolabeling techniques for liposomes.
• Analysis of preclinical and clinical studies on liposome biodistribution using advanced imaging systems.
• Discussion of the integration of imaging data with nanomedicine for theranostic applications.

Main Results:

• Radiolabeling of liposomes has been crucial for evaluating in vivo performance in preclinical drug development.
• Advanced imaging systems facilitate non-invasive monitoring of liposome biodistribution in humans.
• Developments in radiolabeling and imaging open new possibilities for nanomedicine in personalized patient care.

Conclusions:

• Radiolabeled liposomes represent a powerful tool for theranostics in personalized medicine.
• Imaging of nanocarriers can guide patient selection and monitor treatment response.
• Further development in this field holds significant potential for improving cancer therapy and diagnostics.